New Market Report: R&D Trends: Allergic Rhinitis - Immunotherapy dominates the pipeline

Aug. 6, 2012 - PRLog -- The 2012 pipeline shows continued strong interest in immunotherapy, which makes up 43% of products in development. Advancements in clinical trials and key partnerships are increasing exposure of this class. In this largely stable market, areas of innovation exist with nasal antihistamine/corticosteroid combinations showing progress, while a number of novel targeted therapies raise skepticism.

Report Scope

* Assessment of the allergic rhinitis pipeline, drawing out trends by class and the potential to address unmet needs.
* Analysis of clinical trial design, highlighting innovation and anticipated future changes, with a focus on recent developments in immunotherapy.
* Discussion of novel early-stage approaches and the future of treatment in allergic rhinitis, with insight from key opinion leaders.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/434366_rd_trends_allergic_rhinitis_immunotherapy.aspx
------------------------------------------------------------

Report Highlights

Datamonitor has identified 65 products in development for allergic rhinitis. The late-stage pipeline is heavily skewed towards immunotherapy, which makes up all 15 Phase III products. Immunotherapy shows the greatest innovation, with considerable change to clinical trials, and an increased focus on sublingual tablet franchises.

Discussions with key opinion leaders reveal a largely stable market for symptomatic treatment; however, areas of innovation exist, such as the development of combination products. Analysis of comparator therapies highlights areas of unmet need.

A number of novel targeted therapies are moving through the pipeline, including five CRTH2 antagonists. Key opinion leaders and recent discontinuations have cast skepticism over their clinical viability, with efficacy expected to fall short of established treatment classes. However, they may find a place in the treatment of select patient groups

Reasons to Get this Report

* Which characteristics of symptomatic treatments can be improved upon, and what would it take to create a new gold standard?
* What are the driving forces behind allergic rhinitis clinical trial design and how has it evolved?
* To what extent will the growing investment in immunotherapy change the future of treatment?
* Is there value in novel targeted therapies or will current treatments continue to dominate?

Report Table of Contents:

OVERVIEW

* Catalyst
* Summary

EXECUTIVE SUMMARY

* Strategic scoping and focus
* Datamonitor key findings
* Related reports

CLINICAL PIPELINE OVERVIEW

* Allergen immunotherapy dominates late-stage pipeline
* Analysis by formulation demonstrates innovation in the pipeline
* Late-stage discontinued development compounds

* Setipiprant (Actelion)
* QAV-680 (Novartis)
* CDX-313 (CyDex)
* ALK-Flex SQ (ALK-Abello)

TARGET PRODUCT PROFILE

* Telfast/Allegra (fexofenadine; Sanofi)

* Pivotal trial data for Telfast/Allegra

* Nasonex (mometasone; Merck & Co.)

* Pivotal trial data for Nasonex

* Target product profile versus current level of attainment

CLINICAL TRIAL DESIGN IN ALLERGIC RHINITIS

* Trends in clinical trial endpoints

* Symptom scores

* Allergy challenges tackle seasonal variations
* Study populations
* Comparator drugs
* Drug development guidelines in allergen immunotherapy
* Typical allergic rhinitis clinical trials

* Symptomatic treatment
* Allergen immunotherapy

* Future developments in clinical trial design

INNOVATIVE EARLY-STAGE APPROACHES

* Sublingual immunotherapy franchises
* Histamine H4 receptor antagonist
* Novel targeted therapies

THE FUTURE OF TREATMENT IN ALLERGIC RHINITIS

* Dry aerosol steroid sprays and combination antihistamine/corticosteroid therapy
* Sublingual shift in immunotherapy

BIBLIOGRAPHY

* Journal papers
* Websites

APPENDIX

* Contributing experts
* Conferences attended
* Report methodology

TABLES

* Table: Products in development for allergic rhinitis, 2012
* Table: Recently discontinued pipeline candidates for allergic rhinitis, 2012
* Table: Telfast/Allegra (fexofenadine; Sanofi) - drug profile, 2012
* Table: Overview of pivotal trial data for Telfast/Allegra, 2012
* Table: Nasonex (mometasone; Merck & Co.) - drug profile, 2012
* Table: Overview of pivotal trial data for Nasonex, 2012
* Table: Telfast/Allegra and Nasonex vs the minimum acceptable product profile and target product profile, 2012
* Table: Typical Phase III clinical trial design in allergic rhinitis, 2012
* Table: Allergen immunotherapy candidates undergoing Phase III clinical trials, 2012
* Table: Most promising innovative therapeutic approaches in allergic rhinitis, 2012
* Table: Novel targeted therapies in development for allergic rhinitis, March 2012

FIGURES

* Figure: Allergic rhinitis pipeline, by highest development phase, 2012
* Figure: Allergic rhinitis clinical pipeline, by development stage and class, 2012
* Figure: Allergic rhinitis clinical pipeline, by formulation and class, 2012
* Figure: Average Adjusted Symptom Score example
* Figure: Phase III trial of Oralair allergen immunotherapy, 2012

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.